Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluar el ensayo clínico de fase III de la inyección de TQH2722 en el tratamiento de la dermatitis atópica de moderada a grave

Un ensayo clínico de fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de la inyección de TQH2722 en el tratamiento de la dermatitis atópica de moderada a grave en sujetos

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Descripción general del estudio

Estado

Terminado

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Actual)

500

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Anhui
      • Bengbu, Anhui, Porcelana, 233004
        • The First Affiliated Hospital of Bengbu Medical College
      • Tongling, Anhui, Porcelana, 244000
        • Tongling People's Hospital
      • Wuhu, Anhui, Porcelana, 241000
        • The Second Affiliated Hospital of Wannan Medical College
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100050
        • Beijing Friendship Hospital, Capital Medical University
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400010
        • The First Affiliated Hospital of Chongqing Medical University
      • Chongqing, Chongqing Municipality, Porcelana, 400038
        • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University
      • Chongqing, Chongqing Municipality, Porcelana, 400072
        • The Second Affiliated Hospital of Chongqing Medical University
      • Chongqing, Chongqing Municipality, Porcelana, 404100
        • Chongqing Three Gorges Medical College affiliated People's Hospital
    • Fujian
      • Xiamen, Fujian, Porcelana, 361021
        • The Second Affiliated Hospital of Xiamen Medical College
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510000
        • Dermatology Hospital of Southern Medical UniversityDermatology Hospital of Southern Medical University
      • Guangzhou, Guangdong, Porcelana, 510000
        • The Second Affiliated Hospital of Guangzhou Medical University
      • Shenzhen, Guangdong, Porcelana, 518036
        • Peking University Shenzhen Hospital
    • Guangxi
      • Liuzhou, Guangxi, Porcelana, 545006
        • Liuzhou People's Hospital
    • Hebei
      • Cangzhou, Hebei, Porcelana, 061012
        • Cangzhou Central Hospital
      • Chengde, Hebei, Porcelana, 067000
        • The Affiliated Hospital of Chengde Medical College
    • Heilongjiang
      • Harbin, Heilongjiang, Porcelana, 150036
        • Heilongjiang Provincial Hospital
      • Harbin, Heilongjiang, Porcelana, 151100
        • The Second Affiliated Hospital of Harbin Medical University
      • Qiqihar, Heilongjiang, Porcelana, 161005
        • Qiqihar Hospital of Traditional Chinese Medicine
    • Henan
      • Anyang, Henan, Porcelana, 455001
        • Anyang District Hospital, Puyang City
      • Luoyang, Henan, Porcelana, 471000
        • The Second Affiliated Hospital of Henan University of Science and Technology
      • Nanyang, Henan, Porcelana, 473000
        • Nanyang city first People's Hospital
      • Sanmenxia, Henan, Porcelana, 472000
        • Sanmenxia Central Hospital
      • Zhengzhou, Henan, Porcelana, 450000
        • Henan Provincial People's Hospital
      • Zhengzhou, Henan, Porcelana, 471000
        • The First Affiliated Hospital of Henan University of Science and Technology
    • Hubei
      • Jingzhou, Hubei, Porcelana, 434000
        • Jingzhou Central Hospital
      • Wuhan, Hubei, Porcelana, 430060
        • Wuhan University People's Hospital
      • Yichang, Hubei, Porcelana, 443003
        • Yichang Central People's Hospital
    • Hunan
      • Changsha, Hunan, Porcelana, 410013
        • Xiangya Third Hospital, Central South University
      • Changsha, Hunan, Porcelana, 410011
        • The Second Xiangya Hospital, Central South University
      • Hengyang, Hunan, Porcelana, 421001
        • The First Affiliated Hospital of University of South China
      • Huaihua, Hunan, Porcelana, 418000
        • Hunan Medical University General Hospital
    • Inner Mongolia
      • Baotou, Inner Mongolia, Porcelana, 14017
        • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
      • Baotou, Inner Mongolia, Porcelana, 14040
        • Baotou Central Hospital
      • Hohhot, Inner Mongolia, Porcelana, 10000
        • Affiliated Hospital of Inner Mongolia Medical University
    • Jiangsu
      • Changzhou, Jiangsu, Porcelana, 213000
        • Changzhou First People's Hospital
      • Suzhou, Jiangsu, Porcelana, 215000
        • The Second Affiliated Hospital of Soochow University
      • Suzhou, Jiangsu, Porcelana, Weiling
        • Suzhou Municipal Hospital
      • Xuzhou, Jiangsu, Porcelana, 221132
        • Affiliated Hospital of Xuzhou Medical University
      • Yancheng, Jiangsu, Porcelana, 224005
        • Yancheng First People's Hospital
      • Zhenjiang, Jiangsu, Porcelana, 210039
        • Affiliated Hospital of Jiangsu University
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 330006
        • The Second Affiliated Hospital of Nanchang University
    • Jilin
      • Changchun, Jilin, Porcelana, 130041
        • Second Hospital of Jilin University
    • Liaoning
      • Panjin, Liaoning, Porcelana, 124120
        • Panjin Liao oil precious stone flower hospital
    • Ningxia
      • Yinchuan, Ningxia, Porcelana, 750010
        • Yinchuan First People's Hospital
    • Qinghai
      • Xining, Qinghai, Porcelana, 810000
        • Affiliated Hospital of Qinghai University
    • Shandong
      • Dezhou, Shandong, Porcelana, 277102
        • Dezhou People's Hospital
      • Jinan, Shandong, Porcelana, 250012
        • Shandong University Qilu Hospital
      • Liaocheng, Shandong, Porcelana, 252000
        • Liaocheng People's Hospital
      • Yantai, Shandong, Porcelana, 264000
        • Yantai Yuhuangding Hospital
      • Zaozhuang, Shandong, Porcelana, 277102
        • Zaozhuang Municipal Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 545006
        • Shanghai Dermatology Hospital
    • Shanxi
      • Baoji, Shanxi, Porcelana, 721008
        • Baoji Central Hospital
      • Taiyuan, Shanxi, Porcelana, 030000
        • Shanxi Provincial People's Hospital
      • Taiyuan, Shanxi, Porcelana, 030009
        • Peking University First Hospital Taiyuan Hospital
      • Xi’an, Shanxi, Porcelana, 710004
        • The Second Affiliated Hospital of Xi 'an Jiaotong University
      • Xi’an, Shanxi, Porcelana, 710032
        • The First Affiliated Hospital of PLA Air Force Medical University
      • Xi’an, Shanxi, Porcelana, 710032
        • The First Affiliated Hospital of Xi 'an Medical College
      • Xi’an, Shanxi, Porcelana, 710032
        • The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610000
        • Sichuan Provincial People's Hospital
      • Chengdu, Sichuan, Porcelana, 610000
        • Chengdu Second People's Hospital
      • Chengdu, Sichuan, Porcelana, 610072
        • Chengdu Second People's Hospital
      • Luzhou, Sichuan, Porcelana, 646000
        • Affiliated Hospital of Southwest Medical University
      • Suining, Sichuan, Porcelana, 629000
        • Suining Central Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300120
        • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
      • Tianjin, Tianjin Municipality, Porcelana, 300190
        • Tianjin First Central Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, Porcelana, 830002
        • People's Hospital of Xinjiang Uygur Autonomous Region
      • Ürümqi, Xinjiang, Porcelana, 830002
        • Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
    • Yunnan
      • Kunming, Yunnan, Porcelana, 650032
        • The First Affiliated Hospital of Kunming Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310006
        • Hangzhou First People's Hospital
      • Hangzhou, Zhejiang, Porcelana, 310009
        • Hangzhou Third People's Hospital
      • Jiaxing, Zhejiang, Porcelana, 545006
        • Jiaxing second Hospital
      • Jinhua, Zhejiang, Porcelana, 321000
        • Jinhua Central Hospital
      • Ningbo, Zhejiang, Porcelana, 315211
        • The First Affiliated Hospital of Ningbo University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • The age of signing the informed consent is 18-75 years old, regardless of gender.
  • Meet the 2014 American Academy of Dermatology (AAD) standards, diagnosed as AD.
  • During screening and baseline visit, eczema area and severity score (EASI) ≥16 points; Investigator global score (IGA) ≥3 points; Affected body surface area (BSA) ≥10%; Baseline pruritus Peak Value Scale (NRS) weekly mean ≥4 points.
  • Have received at least 4 weeks of moderate-to-strong action or at least 2 weeks of super effective external glucocorticoid (TCS) treatment or sufficient duration of systemic glucocorticoid treatment, the efficacy is not sufficient; Or subjects cannot receive the above treatment due to adverse reactions or potential risks.

Exclusion Criteria:

  • Used immunosuppressants/immunomodulatory drugs, ultraviolet phototherapy, systemic Chinese medicine treatment within 4 weeks before randomization.
  • Received topical calcineurin inhibitors (TCS), topical calcineurin inhibitors (TCI), and other topical preparations within 2 weeks before randomization.
  • Received anti-interleukin-4 receptor alpha (IL-4R) monoclonal antibodies, anti-ige monoclonal antibodies, or other biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.
  • Had received live attenuated vaccine within 12 weeks prior to randomization or planned to receive it during the study period.
  • Use of antihistamines within 1 week prior to randomization (unless you have received steady doses of antihistamines for at least 7 days).
  • Received allergen specific immunotherapy within 6 months before randomization.
  • There are skin comorbidities that may interfere with study evaluation.
  • There is a history of clinically significant illness that the investigator believes poses a risk to the safety of the subject and is poorly controlled.
  • A known or suspected history of immunosuppression (immune deficiency).
  • Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and papillary thyroid carcinoma that have been cured for more than 5 years prior to the screening period).
  • Subject may have active Mycobacterium tuberculosis infection.
  • Subjects with severe liver and kidney function impairment.
  • Screening period HIV antibody positive, or have a history of HIV infection.
  • Screening period of treponema pallidum antibody positive.
  • Participated in clinical trials of other drugs or medical devices within 12 weeks prior to randomization.
  • Treatment-requiring infections were present in the 4 weeks prior to randomization.
  • During the study period, subjects plan to undergo major surgical operations.
  • Pregnant or lactating women.
  • Alcohol, drug abuse and known drug dependence.
  • History of atopic keratoconjunctivitis with corneal involvement.
  • The subject has any medical or psychiatric symptoms that interfere with participation in the study or with the interpretation of the study results.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: TQH2722 injection

TQH2722 injection, 14 days for a treatment cycle

Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody

Comparador de placebos: Placebo of TQH2722 injection

Placebo of TQH2722 injection, 14 days for a treatment cycle

Placebo without drug substance

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participants who achieved EASI-75 (≥75% improvement from baseline) on the eczema Area and Severity score (EASI)
Periodo de tiempo: Baseline to 16 weeks after treatment

Percentage of participants who achieved EASI-75 (≥75% improvement from baseline) on the eczema Area and Severity score (EASI)

Baseline to 16 weeks after treatment
Subjects with an Investigator's Overall Rating (IGA) score (5-scale) of 0 or 1 and ≥2 points decline from baseline
Periodo de tiempo: Baseline to 16 weeks after treatment

Percentage of subjects with an Investigator's Overall Rating (IGA) score (5-scale) of 0 or 1 and ≥2 points decline from baseline.

Baseline to 16 weeks after treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The incidence of adverse events
Periodo de tiempo: After medication to 60 weeks

Adverse events that occur during treatment

After medication to 60 weeks
Steady valley concentration of TQH2722
Periodo de tiempo: After medication to 60 weeks

Relatively stable concentration levels of TQH2722

After medication to 60 weeks
The incidence and titer of drug-resistant antibodies (ADA) in subjects
Periodo de tiempo: After medication to 60 weeks

The incidence and titer of drug-resistant antibodies (ADA) in subjects

After medication to 60 weeks
Incidence of neutralizing antibodies (Nab)
Periodo de tiempo: After medication to 60 weeks

Incidence of neutralizing antibodies (Nab)

After medication to 60 weeks
Eczema area and severity score (EASI) change from baseline
Periodo de tiempo: From baseline to week 60

The affected area of each site was assessed. According to the percentage of the affected area, the corresponding Region score was 0 to 6. The higher the score, the more severe the involvement.

From baseline to week 60
Rate of change from baseline in the Investigator's overall Score (IGA)
Periodo de tiempo: After medication to 60 weeks

The researchers assessed the form of the dermatitis using a 5-point scale (0-5), with higher scores being more severe.

After medication to 60 weeks
Change of body surface area from baseline in moderate to severe atopic dermatitis
Periodo de tiempo: After medication to 60 weeks

The researchers used a nine-point scale to assess the percentage of AD affected area in the whole body (0-100%), with the larger the value, the more severe the involvement.

After medication to 60 weeks
Change rate of atopic dermatitis score (SCORAD) from baseline
Periodo de tiempo: After medication to 60 weeks

According to the involvement of skin surface area, the severity of skin lesions and the subjective symptom score, the higher the value, the more severe the dermatitis.

After medication to 60 weeks
Change in daily Peak Itch Digital Rating Scale (NRS) score from baseline
Periodo de tiempo: After medication to 60 weeks

Rate the most severe itching in the past 24 hours on a scale of 0-10, with higher numbers being more severe.

After medication to 60 weeks
Rate of change in dermatological quality of life (DLQI) score from baseline
Periodo de tiempo: After medication to 60 weeks

Assess how much the skin problems of the last week have affected the subjects' lives

After medication to 60 weeks
Change in patients' self-assessment of eczema (POEM) from baseline
Periodo de tiempo: After medication to 60 weeks

The number of days in the past 7 days to assess whether eczema caused skin problems such as itching and bleeding, 0 indicates no days, 1 indicates 1-2 days, 2 indicates 3-4 days, 3 indicates 5-6 days, and 4 indicates all days.

After medication to 60 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de octubre de 2024

Finalización primaria (Actual)

11 de septiembre de 2025

Finalización del estudio (Actual)

18 de julio de 2026

Fechas de registro del estudio

Enviado por primera vez

8 de agosto de 2024

Primero enviado que cumplió con los criterios de control de calidad

12 de agosto de 2024

Publicado por primera vez (Actual)

14 de agosto de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir